MedPath

Compass Pathways Cuts 30% of Workforce Amid Phase 3 Trial Delays

• Compass Pathways is reducing its workforce by approximately 30% due to changing timelines for its Phase 3 trials of COMP360. • The restructuring aims to focus the organization and its capital resources on the successful delivery of the COMP360 program. • Non-COMP360 preclinical efforts will be discontinued, and the company is exploring externalization options for its digital health tools. • The workforce reduction includes the elimination of some senior management positions within the company.

Compass Pathways (CMPS) has announced a 30% reduction in its workforce, including the elimination of some senior management positions, following adjustments to the timelines for its Phase 3 trials. The decision, revealed alongside recent earnings reports, is intended to concentrate the company's resources on the successful advancement of its COMP360 program.
The company's strategic shift involves halting all non-COMP360 preclinical activities. Compass Pathways is also considering externalizing its digital health tools to further streamline operations and allocate capital more effectively. This move reflects a renewed focus on its core clinical development program.
"to further focus the organization and its capital resources on successfully delivering the COMP360 program."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.
Several companies, including Intellia Therapeutics and IGM Biosciences, are cutting a significant portion of their workforce to focus on key programs and extend cash runways.

Eyenovia's Stock Plummets After Phase III Myopia Trial Fails to Meet Primary Endpoint

Eyenovia's stock price plummeted after its Phase III CHAPERONE study, evaluating a drug-device combination for pediatric progressive myopia, failed to meet its primary endpoint.
The CHAPERONE trial assessed low-dose atropine delivered via the Optejet platform but did not demonstrate a statistically significant difference in myopia progression compared to the comparator arm.

Marinus Pharmaceuticals Cuts 45% of Workforce After Ganaxolone Trial Failure

Marinus Pharmaceuticals announced a workforce reduction of approximately 45% following disappointing Phase III trial results for oral ganaxolone in tuberous sclerosis complex.
The TrustTSC trial, evaluating ganaxolone, did not meet its primary endpoint, leading Marinus to discontinue further clinical development of the oral drug.

23andMe Halts Therapeutics Division and Cuts 40% of Workforce Amid Restructuring

23andMe is discontinuing its therapeutics division and laying off 40% of its workforce, impacting over 200 employees, to reduce operating expenses.
The company cites a focus on its core consumer business and research partnerships as the primary driver for this restructuring.

COMPASS Pathways Announces Delay in COMP360 Trial Data and Restructuring

COMPASS Pathways delays COMP360 trial data release; COMP005 results expected Q2 2025, COMP006 in second half of 2026 due to recruitment challenges.
The company is reducing its workforce by 30% and halting non-COMP360 preclinical efforts to preserve cash and focus on pivotal trials for treatment-resistant depression (TRD).

Compass Pathways Delays Phase III Psilocybin Trial Readouts and Reduces Workforce

Compass Pathways has delayed the Phase III trial readouts for its psilocybin-based therapy (COMP360) for treatment-resistant depression, pushing the data release for COMP005 to Q2 2025.
The readout for the COMP006 trial, a two-dose study, has been postponed to the second half of 2026 due to increased regulatory scrutiny regarding functional unblinding.

Compass Pathways Restructures, Cuts Staff Amid Psilocybin Trial Delays

Compass Pathways is cutting 30% of its staff and halting early-stage research to focus on late-stage trials of its lead drug COMP360.
The company anticipates top-line data from its main Phase 3 trial in Q2 2025, with results from a second late-stage study pushed to H2 2026.

COMPASS Pathways Reports Financials and Progress on COMP360 Psilocybin Program

COMPASS Pathways' operating expenses increased to $47.9 million for the quarter ending September 30, 2024, driven by advancing clinical programs.
The company's Phase 3 program for COMP360 psilocybin treatment in treatment-resistant depression (TRD) is ongoing, with top-line data expected in 2025 and 2026.

Relay Therapeutics Announces Workforce Reduction to Streamline Research

Relay Therapeutics is laying off approximately 10% of its workforce, affecting about 30 employees, as part of a streamlining effort to enhance research efficiency.
The restructuring aims to save the company around $50 million annually, following a reported net loss of $92.2 million in the second quarter of 2024.

Acelyrin Shifts Focus to Thyroid Eye Disease Drug, Halts Further Investment in Izokibep

Acelyrin will discontinue development of izokibep for hidradenitis suppurativa and psoriatic arthritis despite positive trial data, due to strategic prioritization.
The company will now focus on lonigutamab, an experimental antibody treatment for thyroid eye disease, advancing directly to Phase 3 trials.

Reference News

[1]
Compass Pathways cuts 30% of workforce on Phase 3 trial delays - Yahoo Finance
finance.yahoo.com · Nov 2, 2024

Compass Pathways (CMPS) cuts 30% of workforce, including senior management, due to Phase 3 trial delays, halting non-COM...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy